The firm's real-time PCR assay for rapid detection and differentiation of novovirus genogroup I and II runs on the Aries sample-to-answer system.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The real-time PCR, sample-to-answer assay provides surveillance of whooping cough, a contagious respiratory disease, in clinically symptomatic patients.
Assay revenues rose 38 percent to $37.4 million and infectious disease sales made up about 82 percent of the firm's total Q1 assay sales.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
The firm reported that revenues for Nanosphere, which Luminex acquired in 2016, were up 39 percent year-over-year.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Executives from Luminex and Exact Sciences provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The firm also reported that 2016 preliminary revenues were up 14 percent, and that Nanosphere MDx platform revenues rose 32 percent.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.